| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nearly six years after launching a joint venture with IQVIA’s contract research progenitor, Quintiles, Quest Diagnostics is handing over the remainder of its minority share in return for $760 million in cash.
Quest Diagnostics is offering $0 out-of-pocket testing. Drive-thru testing is available Monday through Friday, from 9 a.m. to 4 a.m. Partnering with Walmart locations, appointments can be made through Quest Diagnostics’ online portal.
The COVID-19 pandemic affected diagnostic testing much like it did other parts of the healthcare delivery system — it demanded completely novel approaches at some points, and merely accelerated trends underway at others. In other words, an evolution became a revolution. That revolution, according to Quest Diagnostics Chief Medical Officer Jay Wohlgemuth, MD, can be categorized by just a few words, most notably “convenience.”
Quest Diagnostics recently signed a non-exclusive license agreement with Zora Biosciences Oy, a renowned clinical diagnostics company working to identify robust markers of disease. The agreement is expected to enable Quest Diagnostics in the development of a test service based on Zora's patented ceramide-analysis technology.
With the COVID-19 pandemic accelerating interest in telehealth and consumer-initiated testing, Quest Diagnostics is expanding its existing DTC operation to try to capture $250 million of the emerging market.